Acutaas Chemicals
- Market cap
- ₹ 25,802 Cr.
- P/E
- 66.5x
- P/B
- 15.92x
- 52-week range
- 1,570 – 3,900
- ROE
- 24%
- ROCE
- 32%
- Dividend yield
- 0.1%
- Debt / equity
- 0.02
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Acutaas Chemicals Limited, formerly Ami Organics Limited, is an India-based company, which is engaged in the manufacturing of pharma intermediates and specialty chemicals. It is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE) and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other industries. It manufactures pharma intermediates for certain active pharmaceutical ingredients (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. It has developed and commercialized over 610 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Acutaas Chemicals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)66.5 against a typical 33.2: pricier than most peers (1st = cheapest).174th of 220
- Sales growth+59.4% against a typical +15.6% from a year earlier.24th of 197
- Profit growth+70.5% against a typical +18.9% from a year earlier.40th of 160
- Share price, 3 months+14.8% against a typical −2%.43rd of 200
- Size₹ 25,802.1 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).21st of 199
Latest announcements
Exchange filings and their impact on the company.
- Blockbuster H1 with ~48% revenue and ~70-80% profit growth plus Korea semiconductor plant in trials points to 25-30% growth ahead.
Acutaas Chemicals reported strong Q2 and H1 FY27 results, with standalone Q2 profit of about Rs 135.7 crore versus Rs 72.9 crore last year and H1 consolidated revenue of about Rs 788.6 crore versus Rs 531.3 crore last year. Its step-down subsidiary Indichem Inc inaugurated a semiconductor materials plant in Gongju, South Korea on August 28, 2026 after about Rs 200 crore investment, which was under trial runs at quarter-end. Strong operating cash flow funded capex while cash balances rose and borrowings fell, supporting further growth over the next year.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A+ by CARE- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CARE | CARE A+ / CARE A1+ | Stable | 9 Dec 2025 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 9 Dec 2025 | Reaffirmed | CARE A+ / CARE A1+ | — | CARE | ₹ 135 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 27 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 24 Jul 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 30 Apr 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 28 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 17 Oct 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 30 Jul 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 172 | 166 | 225 | 177 | 247 | 275 | 308 | 207 | 306 | 393 | 433 | 330 |
| Expenses | 148 | 140 | 182 | 147 | 198 | 206 | 224 | 156 | 211 | 243 | 249 | 217 |
| Operating Profit | 25 | 27 | 43 | 30 | 49 | 69 | 85 | 51 | 95 | 151 | 184 | 113 |
| OPM % | 14% | 16% | 19% | 17% | 20% | 25% | 28% | 25% | 31% | 38% | 42% | 34% |
| Other Income | −30 | 3 | 1 | 1 | 8 | 2 | 6 | 16 | 10 | 5 | 11 | 2 |
| Interest | 1 | 3 | 2 | 4 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 4 | 4 | 5 | 6 | 7 | 6 | 7 | 8 | 8 | 10 | 10 | 10 |
| Profit before tax | −10 | 24 | 37 | 20 | 50 | 63 | 83 | 58 | 96 | 145 | 184 | 104 |
| Tax % | 71% | 25% | 31% | 26% | 25% | 28% | 24% | 24% | 25% | 27% | 27% | 28% |
| Net Profit | −17 | 18 | 26 | 15 | 38 | 45 | 63 | 44 | 72 | 106 | 134 | 75 |
| EPS in Rs | −2.55 | 2.27 | 3.41 | 1.71 | 4.56 | 5.49 | 7.63 | 5.41 | 8.82 | 13.19 | 16.09 | 9.07 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 32%
- 3 Years
- 30%
- TTM
- 41%
- 10 Years
- —
- 5 Years
- 46%
- 3 Years
- 62%
- TTM
- 104%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 70%
- TTM
- —
- 10 Years
- 20%
- 5 Years
- 18%
- 3 Years
- 18%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Acutaas Chemicals | ₹ 3,690.00 | ₹ 25,802 Cr. | 66.5x | 15.9x | 24% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 99.6x | 26.6x | 31.4% | 17.7% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.6x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 110.5x | 14.2x | 13.6% | 21.7% |
Management
- Nareshkumar Ramjibhai Patel
- Executive Chairman of the Board and Managing Director
- Bhavin N. Shah
- Chief Financial Officer
- Chetansinh Parmar
- Chief Information Security Officer
- Ekta Kumari Srivastava
- Company Secretary and Compliance Officer
- Ram Mohan Lokhande
- Whole Time Director
- Virendra Nath Mishra
- Whole Time Director
- Chetankumar Chhaganlal Vaghasia
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.